EGFL6

Summary

EGFL6 (EGF like domain multiple 6, HGNC:3235) is a protein-coding gene on chromosome Xp22.2, encoding Epidermal growth factor-like protein 6 (Q8IUX8). May bind integrin alpha-8/beta-1 and play a role in hair follicle morphogenesis.

This gene encodes a member of the epidermal growth factor (EGF) repeat superfamily. Members of this superfamily are characterized by the presence of EGF-like repeats and are often involved in the regulation of cell cycle, proliferation, and developmental processes. The gene product contains a signal peptide, suggesting that it is secreted; an EGF repeat region consisting of 4 complete EGF-like repeats and 1 partial EGF-like repeat, 3 of which have a calcium-binding consensus sequence; an arg-gly-asp integrin association motif; and a MAM domain, which is believed to have an adhesive function. This gene is expressed early during development, and its expression has been detected in lung and meningioma tumors.

Source: NCBI Gene 25975 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 124 total
• MANE Select transcript: NM_015507

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3235
Approved symbol	EGFL6
Name	EGF like domain multiple 6
Location	Xp22.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000198759
Ensembl biotype	protein_coding
OMIM	300239
Entrez	25975

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000361306, ENST00000380602, ENST00000473826, ENST00000857786, ENST00000857787

RefSeq mRNA: 2 — MANE Select: NM_015507 NM_001167890, NM_015507

CCDS: CCDS14155, CCDS55370

Canonical transcript exons

ENST00000361306 — 12 exons

Exon	Start	End
ENSE00000665365	13617730	13618053
ENSE00000665368	13619163	13619243
ENSE00000665380	13627011	13627276
ENSE00000840427	13603317	13603436
ENSE00000840428	13606379	13606513
ENSE00000840429	13608324	13608446
ENSE00000893581	13594836	13594928
ENSE00000893582	13599975	13600094
ENSE00001150966	13623824	13623925
ENSE00001279931	13569601	13569935
ENSE00001279946	13589556	13589668
ENSE00001933605	13632985	13633575

Expression profiles

Bgee: expression breadth ubiquitous, 186 present calls, max score 96.77.

FANTOM5 (CAGE): breadth broad, TPM avg 1.3909 / max 193.5050, expressed in 232 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
195571	1.0495	214
195573	0.2233	59
195572	0.0827	28
195574	0.0353	16

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
visceral pleura	UBERON:0002401	96.77	gold quality
placenta	UBERON:0001987	95.68	gold quality
pleura	UBERON:0000977	93.13	gold quality
parietal pleura	UBERON:0002400	92.27	gold quality
skin of hip	UBERON:0001554	90.72	gold quality
cartilage tissue	UBERON:0002418	90.37	gold quality
hair follicle	UBERON:0002073	88.88	gold quality
lower lobe of lung	UBERON:0008949	88.73	gold quality
lung	UBERON:0002048	87.84	gold quality
esophagus squamous epithelium	UBERON:0006920	87.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.11	gold quality
upper lobe of lung	UBERON:0008948	86.60	gold quality
upper lobe of left lung	UBERON:0008952	86.11	gold quality
mucosa of paranasal sinus	UBERON:0005030	85.63	gold quality
epithelium of esophagus	UBERON:0001976	85.52	gold quality
right lung	UBERON:0002167	84.58	gold quality
bronchial epithelial cell	CL:0002328	84.04	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.83	gold quality
epithelium of bronchus	UBERON:0002031	79.95	gold quality
squamous epithelium	UBERON:0006914	79.34	gold quality
bronchus	UBERON:0002185	79.04	gold quality
pigmented layer of retina	UBERON:0001782	77.14	gold quality
endothelial cell	CL:0000115	75.99	gold quality
adipose tissue	UBERON:0001013	75.91	gold quality
subcutaneous adipose tissue	UBERON:0002190	75.81	gold quality
germinal epithelium of ovary	UBERON:0001304	75.79	gold quality
connective tissue	UBERON:0002384	74.56	gold quality
esophagus mucosa	UBERON:0002469	72.79	gold quality
urinary bladder	UBERON:0001255	71.88	gold quality
cervix squamous epithelium	UBERON:0006922	71.31	silver quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	4012.45
E-HCAD-24	yes	3244.10
E-HCAD-23	yes	3109.89
E-CURD-126	yes	1489.16
E-MTAB-8221	yes	1068.71
E-MTAB-10662	yes	990.37
E-MTAB-10042	yes	8.42
E-ANND-3	yes	5.69

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

47 targeting EGFL6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-202-5P	99.78	67.65	991
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-888-3P	99.53	69.77	1057
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-150-3P	99.43	70.51	920

Literature-anchored findings (GeneRIF, showing 17)

• There is an absence of GNAS and EGFL6 mutations in common human cancers. (PMID:18038328)
• results indicate that human EGFL6 is a paracrine/autocrine growth factor of adipose tissue up-regulated in obesity and potentially involved in the process of adipose tissue expansion and the development of obesity (PMID:20574786)
• EGFL6 was overexpressed in benign meningioma tissues and serum. (PMID:23285163)
• EGFL6 is an angiocrine and tumor cell factor that promotes tumorigenesis via SHP2-mediated signaling. EGFL6 stimulates ALDH+ ovarian cancer stem cell to migrate and undergo asymmetric division. (PMID:27803106)
• In conclusion, our results suggest that plasma level of EGFL6 may be useful to assess disease progression, and especially advanced T status and higher TNM stage in patients with oral squamous cell carcinoma. (PMID:28539817)
• High EGFL6 expression may serve as a marker for poor prognosis of lung adenocarcinoma, especially in younger patients. (PMID:29934389)
• It is an oncogene in CRC oncogenesis and development. (PMID:30395690)
• In summary, we provided evidence that EGFL6 was highly expressed in nasopharyngeal carcinoma (NPC), and was associated with migration and growth of NPC cells. (PMID:30444069)
• EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis (PMID:30455428)
• Results showed that EGFL6 may play an important role in the adenomacarcinoma process, and high expression predicted poor survival in colorectal cancer (CRC) patients. These findings provide evidence for EGFL6 is a novel inducer of proliferation in CRC, partially through the activation of beta-catenin via the WNT pathway. As a secreted protein, EGFL6 induces its function via secreted proteins targeting CRC cells. (PMID:30693973)
• Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation. (PMID:32008086)
• Upregulation of miR126 inhibits podocyte injury in sepsis via EGFL6/DKC1 signaling pathway. (PMID:33760211)
• Epidermal growth factor-like domain protein 6 recombinant protein facilitates osteogenic differentiation in adipose stem cells via bone morphogenetic protein 2/recombinant mothers against decapentaplegic homolog 4 signaling pathway. (PMID:35220882)
• Transcriptome Analyses of Adipose Tissue Samples Identify EGFL6 as a Candidate Gene Involved in Obesity-Related Adipose Tissue Dysfunction in Children. (PMID:35457174)
• EGFL6 promotes endometrial cancer cell migration and proliferation. (PMID:38368816)
• Cytoplasmic Expression of the EGFL6 Protein Is an Independent Prognostic Factor for Shortened Patient Survival in Human Hepatocellular Carcinoma. (PMID:39187367)
• Egfl6 promotes ovarian cancer progression by enhancing the immunosuppressive functions of tumor-associated myeloid cells. (PMID:39312740)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	egfl6	ENSDARG00000045958
mus_musculus	Egfl6	ENSMUSG00000000402
rattus_norvegicus	Egfl6	ENSRNOG00000004275

Paralogs (1): NPNT (ENSG00000168743)

Protein

Protein identifiers

Epidermal growth factor-like protein 6 — Q8IUX8 (reviewed: Q8IUX8)

Alternative names: MAM and EGF domains-containing gene protein

All UniProt accessions (1): Q8IUX8

UniProt curated annotations — full annotation on UniProt →

Function. May bind integrin alpha-8/beta-1 and play a role in hair follicle morphogenesis. Promotes matrix assembly.

Subcellular location. Secreted. Extracellular space. Extracellular matrix. Basement membrane.

Similarity. Belongs to the nephronectin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IUX8-1	1	yes
Q8IUX8-2	2

RefSeq proteins (2): NP_001161362, NP_056322* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000152	EGF-type_Asp/Asn_hydroxyl_site	PTM
IPR000742	EGF	Domain
IPR000998	MAM_dom	Domain
IPR001881	EGF-like_Ca-bd_dom	Domain
IPR009030	Growth_fac_rcpt_cys_sf	Homologous_superfamily
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR018097	EGF_Ca-bd_CS	Conserved_site
IPR049883	NOTCH1_EGF-like	Domain
IPR052235	Nephronectin_domain	Family

Pfam: PF00629, PF07645

UniProt features (33 total): disulfide bond 8, sequence conflict 7, domain 6, sequence variant 4, compositionally biased region 2, signal peptide 1, chain 1, glycosylation site 1, splice variant 1, region of interest 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IUX8-F1	65.96	0.06

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (8): 98–109, 105–118, 120–132, 178–191, 185–200, 223–236, 230–245, 247–258

Glycosylation sites (1): 397

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 141 (showing top): RNGTGGGC_UNKNOWN, MULLIGHAN_NPM1_SIGNATURE_3_UP, BENPORATH_ES_WITH_H3K27ME3, BOYLAN_MULTIPLE_MYELOMA_PCA1_DN, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN, IRF7_01, LU_TUMOR_VASCULATURE_UP, GNF2_KISS1, IRF_Q6, GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION, SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_UP, GNF2_CDKN1C, GOCC_BASEMENT_MEMBRANE, VANTVEER_BREAST_CANCER_ESR1_DN

GO Biological Process (4): cell adhesion (GO:0007155), positive regulation of cell-substrate adhesion (GO:0010811), cell differentiation (GO:0030154), extracellular matrix organization (GO:0030198)

GO Molecular Function (3): integrin binding (GO:0005178), calcium ion binding (GO:0005509), protein binding (GO:0005515)

GO Cellular Component (5): basement membrane (GO:0005604), obsolete extracellular space (GO:0005615), membrane (GO:0016020), extracellular region (GO:0005576), extracellular matrix (GO:0031012)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cellular process	1
regulation of cell-substrate adhesion	1
cell-substrate adhesion	1
positive regulation of cell adhesion	1
cellular developmental process	1
extracellular structure organization	1
external encapsulating structure organization	1
signaling receptor binding	1
protein-containing complex binding	1
cell adhesion molecule binding	1
metal ion binding	1
binding	1
extracellular matrix	1
external encapsulating structure	1

Protein interactions and networks

STRING

1372 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EGFL6	TCEANC	Q8N8B7	561
EGFL6	ITGA8	P53708	536
EGFL6	GEMIN8	Q9NWZ8	493
EGFL6	MEGF9	Q9H1U4	449
EGFL6	CTPS2	Q9NRF8	418
EGFL6	EIF2S3	P41091	398
EGFL6	ANKS3	Q6ZW76	397
EGFL6	ARHGAP28	Q9P2N2	396
EGFL6	AREG	P15514	394
EGFL6	WDR24	Q96S15	392
EGFL6	INSYN2B	A6NMK8	388
EGFL6	EHD4	Q9H223	384
EGFL6	RHBDL3	P58872	377
EGFL6	RHBDL1	O75783	371
EGFL6	LRRC34	Q8IZ02	370

IntAct

10 interactions, top by confidence:

A	B	Type	Score
EGFL6	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
SH3GL2	EGFL6	psi-mi:“MI:0915”(physical association)	0.550
EGFL6	H1-1	psi-mi:“MI:0915”(physical association)	0.400
EGFL6	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
EGFL6	CCDC85C	psi-mi:“MI:0914”(association)	0.350
EGFL6	UBQLN2	psi-mi:“MI:0915”(physical association)	0.000
EGFL6	SH3GL3	psi-mi:“MI:0915”(physical association)	0.000
EGFL6	SH3GL2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (32): CCDC85C (Affinity Capture-MS), ZZEF1 (Affinity Capture-MS), ALG13 (Affinity Capture-MS), SORL1 (Affinity Capture-MS), HECTD3 (Affinity Capture-MS), HDGF (Affinity Capture-MS), LRP2 (Affinity Capture-MS), FAM8A1 (Affinity Capture-MS), SYVN1 (Affinity Capture-MS), IDE (Affinity Capture-MS), LRP1B (Affinity Capture-MS), LDLR (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), SH3GL2 (Two-hybrid), SH3GL3 (Two-hybrid)

ESM2 similar proteins: A7MBS7, D3YXF5, F1LW30, O89103, P10643, P11680, P27918, P35446, P82987, P90884, Q29RQ1, Q2I0M5, Q2MKA7, Q3UPR9, Q3UTY6, Q4R7Z5, Q5M7L6, Q5RAD0, Q5RBP1, Q5RBP8, Q5UE90, Q64181, Q66PY1, Q69ZU6, Q6NZL8, Q6P4U0, Q6UXX9, Q6ZMP0, Q7T3Q2, Q7TSK7, Q80YN4, Q86TH1, Q8BFU0, Q8BJ73, Q8BLI0, Q8IUX8, Q8IWY4, Q8IX30, Q8N6G6, Q8VCC9

Diamond homologs: A0A096LNW5, A2RUV0, B4DH59, G3I6Z6, O35474, O35516, O75095, O89019, P07207, P0DPK3, P0DPK4, P13508, P20749, P21783, P31695, P46530, P46531, P82279, Q01705, Q04721, Q07008, Q20911, Q499M5, Q502K3, Q5RBP1, Q61982, Q6UXI9, Q6UY11, Q7Z3S9, Q810B6, Q8AVH7, Q8IUX8, Q91V88, Q99466, Q9FY48, Q9JJZ5, Q9P2R3, Q9QW30, Q9QXT5, Q9R172

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

124 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	66
Likely benign	7
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

1559 predictions. Top by Δscore:

Variant	Effect	Δscore
X:13603422:G:GT	donor_gain	1.0000
X:13603449:G:GT	donor_gain	1.0000
X:13606370:A:AG	acceptor_gain	1.0000
X:13606371:C:G	acceptor_gain	1.0000
X:13606372:A:AG	acceptor_gain	1.0000
X:13606373:C:G	acceptor_gain	1.0000
X:13606374:CCTA:C	acceptor_loss	1.0000
X:13606376:TAG:T	acceptor_loss	1.0000
X:13606377:A:AC	acceptor_loss	1.0000
X:13606377:A:AG	acceptor_gain	1.0000
X:13606378:G:GT	acceptor_gain	1.0000
X:13606378:GA:G	acceptor_gain	1.0000
X:13606378:GAT:G	acceptor_gain	1.0000
X:13606378:GATA:G	acceptor_gain	1.0000
X:13606378:GATAT:G	acceptor_gain	1.0000
X:13606509:TATAG:T	donor_gain	1.0000
X:13606510:ATAG:A	donor_gain	1.0000
X:13606511:TAGG:T	donor_loss	1.0000
X:13606513:GGT:G	donor_loss	1.0000
X:13606514:G:GG	donor_gain	1.0000
X:13606514:GTAA:G	donor_loss	1.0000
X:13606515:T:G	donor_loss	1.0000
X:13617729:GCT:G	acceptor_gain	1.0000
X:13618049:GTTTT:G	donor_gain	1.0000
X:13618052:TT:T	donor_gain	1.0000
X:13618054:G:GG	donor_gain	1.0000
X:13619161:A:AG	acceptor_gain	1.0000
X:13619161:A:G	acceptor_loss	1.0000
X:13619162:G:GA	acceptor_gain	1.0000
X:13619240:AAAGG:A	donor_loss	1.0000

AlphaMissense

3675 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:13623903:G:C	W421C	0.996
X:13623903:G:T	W421C	0.996
X:13623901:T:A	W421R	0.995
X:13623901:T:C	W421R	0.995
X:13589640:G:C	W53C	0.993
X:13589640:G:T	W53C	0.993
X:13623873:G:C	W411C	0.992
X:13623873:G:T	W411C	0.992
X:13606462:T:A	C202S	0.991
X:13606463:G:C	C202S	0.991
X:13606509:T:G	C217W	0.991
X:13608440:T:A	C258S	0.991
X:13608441:G:C	C258S	0.991
X:13608407:T:A	C247S	0.990
X:13608408:G:C	C247S	0.990
X:13606462:T:C	C202R	0.989
X:13606507:T:C	C217R	0.989
X:13606507:T:A	C217S	0.988
X:13606508:G:C	C217S	0.988
X:13623871:T:A	W411R	0.988
X:13623871:T:C	W411R	0.988
X:13606429:T:A	C191S	0.987
X:13606430:G:C	C191S	0.987
X:13606464:T:G	C202W	0.987
X:13606508:G:A	C217Y	0.987
X:13608401:T:A	C245S	0.987
X:13608402:G:C	C245S	0.987
X:13606390:T:A	C178S	0.986
X:13606391:G:C	C178S	0.986
X:13627228:G:C	W501C	0.986

dbSNP variants (sampled 300 via entrez): RS1000184540 (X:13608822 G>T), RS1000274746 (X:13619670 C>T), RS1000323401 (X:13595843 C>T), RS1000351034 (X:13585009 C>T), RS1000400473 (X:13611735 T>A), RS1000431932 (X:13584586 G>A), RS1000463514 (X:13593849 G>T), RS1000584045 (X:13572175 G>C), RS1000613061 (X:13596264 C>A,T), RS1000626633 (X:13603051 G>A), RS1000691938 (X:13600882 C>T), RS1000701075 (X:13630052 T>A), RS1000749627 (X:13595876 T>C), RS1000801954 (X:13595530 G>A), RS1000814203 (X:13630570 G>A)

Disease associations

OMIM: gene MIM:300239 | disease phenotypes: MIM:258040

GenCC curated gene-disease

Mondo (1): exstrophy-epispadias complex (MONDO:0017919)

Orphanet (2): Exstrophy-epispadias complex (Orphanet:322), Cloacal exstrophy (Orphanet:93929)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001860_15	Multiple sclerosis	4.000000e-06
GCST008388_3	Acute post-radiotherapy pain in breast cancer	8.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	3
Vorinostat	affects cotreatment, increases expression	2
Rotenone	increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
bisphenol A	affects cotreatment, decreases methylation	1
trichostatin A	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV)	increases expression	1
Zoledronic Acid	decreases expression	1
Arsenic Trioxide	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Amiodarone	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	decreases expression	1
Cisplatin	decreases response to substance	1
Cytarabine	decreases expression	1
Doxorubicin	decreases response to substance	1
Indomethacin	increases expression	1
Lipopolysaccharides	affects cotreatment, increases expression	1
Methotrexate	decreases response to substance	1
Plant Extracts	increases expression	1
Silicon Dioxide	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Vincristine	decreases response to substance	1
Cyclosporine	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SL49	HAP1 EGFL6 (-) 1	Cancer cell line	Male
CVCL_SL50	HAP1 EGFL6 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

2 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04760028	PHASE4	COMPLETED	Study on the Influencing Factors of Electroencephalogram Parameters Under Anesthesia
NCT06106425	Not specified	UNKNOWN	Diagnostic and Prognostic Criteria of EEG in Neonatal Convulsions at Assiut University Children Hospital